Vidofludimus
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Vidofludimus
- Molecular weight
- 355.37
- Structure (SMILES)
- COc1cccc(-c2ccc(NC(=O)C3=C(C(=O)O)CCC3)c(F)c2)c1
- 4sc 101
- 4SC-101
- imu 838
- Imu-838
- IMU-838
- IMU-838 tablets
- nsc 717824
- NSC-717824
- sc 12267
- SC-12267
- sc12267
- SC12267
- SC12267 (4SC-101)
- vidofludimus
- Vidofludimus
- vidofludimus [INN]
- VIDOFLUDIMUS [USAN]
- Vidofludimus [WHO-DD]
- vidofludimus inn
- vidofludimus usan
- vidofludimus who dd
- CAS registry numbers
- 717824-30-1
- ChEMBL ID
- CHEMBL197194
- InChIKey
- XPRDUGXOWVXZLL-UHFFFAOYSA-N
- PubChem compound IDs
- 9820008
- FDA ingredient codes (UNII)
- 8Y1PJ3VG81
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- vidofludimus
- Type
- Synthetic organic
- Drug name stem
- -imus
- Action
- Activation
- Action type
- ACTIVATION
- Target
- Nuclear receptor related 1
- Gene symbol
- NR4A2
- Protein identifier
- P43354
- Median affinity
- 6.4
- Affinity units
- pEC50
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- dihydroorotate dehydrogenase (quinone)
- Gene symbol
- DHODH
- Protein identifier
- Q02127
- Median affinity
- 7.32
- Affinity units
- pIC50
- Mechanism
- Dihydroorotate dehydrogenase inhibitor
- Action type
- Inhibitor
- Target
- Dihydroorotate dehydrogenase (quinone), mitochondrial
- Protein identifier
- Q02127
Open Targets mechanisms
- Mechanism
- Dihydroorotate dehydrogenase inhibitor
- Action type
- Inhibitor
- Target
- Dihydroorotate dehydrogenase (quinone), mitochondrial
- Condition
- Arthritis, Rheumatoid
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000685
- Subject identifier
- D001172
- Condition
- Colitis, Ulcerative
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000729
- Subject identifier
- D003093
- Condition
- Inflammatory Bowel Diseases
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003767
- Subject identifier
- D015212
- Condition
- Multiple Sclerosis, Relapsing-Remitting
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003929
- Subject identifier
- D020529
- Condition
- Cholangitis, Sclerosing
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004268
- Subject identifier
- D015209
- Condition
- Multiple Sclerosis
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0005301
- Subject identifier
- D009103
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0100096
- Subject identifier
- D045169
- Condition identifier
- EFO_0000685
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000729
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003767
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003929
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004268
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005011
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005101
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005265
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005301
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0008383
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0018646
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0100096
- Condition identifier
- MONDO_0100096
- Highest recorded phase
- 2
- NCT00820365
- NCT01010581
- NCT03341962
- NCT03722576
- NCT03846219
- NCT05054140
- NCT05134441
- NCT04379271
- NCT04516915
- NCT05201638
- Hydrogen bond acceptors
- 3
- Hydrogen bond donors
- 2
- Polar surface area
- 75.63
- Calculated partition coefficient (ALogP)
- 4
- Calculated partition coefficient (XLogP)
- 3.4
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 5
- Heavy atoms
- 26
- Molecular formula
- C20H18FNO4
- Monoisotopic mass
- 355.12198622
- Natural product
- No
- Recorded assays
- 441
- Active assays
- 106
- Confirmatory
- Other
Oral bioavailability
- Median
- 73.8
- Mean
- 73.8
- Minimum
- 73.8
- Maximum
- 73.8
- Unit
- %
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- F
Related records
Trials (10)
- A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)
- IMU-838 and Oseltamivir in the Treatment of COVID-19
- MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)
- Phase 2 Dose-finding IMU-838 for Ulcerative Colitis
- SC12267 (4SC-101) for Treatment of Patients With Inflammatory Bowel Disease
- SC12267 (4SC-101) in Combination With Methotrexate in Patients With Rheumatoid Arthritis
- Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
- Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
- Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
- Vidofludimus Calcium for Primary Sclerosing Cholangitis
In development for (7)
- COVID-19 Phase 2
- Inflammatory bowel disease Phase 2
- Multiple sclerosis Phase 3
- Relapsing-remitting multiple sclerosis Phase 3
- Rheumatoid arthritis Phase 2
- Sclerosing cholangitis Phase 2
- Ulcerative colitis Phase 2
Targets (1)
- DHODH Dihydroorotate dehydrogenase inhibitor